ReviewCurrent opinion in HIV and AIDS2026
Recapitulating the qualities of HIV-specific CD8 + T cells from spontaneous controllers.
Review in Current opinion in HIV and AIDS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeStudies in spontaneous controllers of HIV and, more recently, post-treatment controllers have shown that effective HIV-specific CD8 + T cell responses may mediate control of the virus in the absence of antiretroviral therapy. The purpose of this review is to first discuss the unique features of HIV-specific CD8 + T cells in spontaneous controllers. We will then explore how qualities of these cells might be harnessed using T cell engineering strategies. SUMMARY OF RECENT
findingsSeveral recent studies have deepened our understanding of HIV-specific CD8 + T cell responses in spontaneous controllers. These have included studies elucidating mechanisms by which preferential antigen restriction, specificity, sensitivity, and breadth promote enhanced T cell responses in spontaneous controllers, as well as studies demonstrating that manipulating the differentiation state or localization of HIV-specific T cells might alter their ability to control the virus. In parallel, many recently-developed approaches to engineer anti-cancer T cells could be used to recapitulate key properties of HIV-specific CD8 + T cells from spontaneous controllers (e.g., sensitive antigen receptors, targeted recognition of evolutionarily conserved and/or mutationally constrained epitopes, T cell stem/memory-like functional capacity). SUMMARY: We identify several opportunities to apply novel approaches being developed in immuno-oncology to enhance the function of engineered T cells for HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.